Biotech New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions December 1, 2025
Featured New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions December 1, 2025
Featured Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 November 13, 2025
Featured Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases November 5, 2025
Biotech BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies November 4, 2025
Biotech BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization October 30, 2025
Featured News BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug October 22, 2025
Featured Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 October 21, 2025
Featured Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 October 17, 2025
Search
biotechnology
December 1, 2025
December 1, 2025
November 13, 2025
November 5, 2025
November 4, 2025
October 30, 2025
October 29, 2025
October 22, 2025
October 21, 2025
October 17, 2025
